Last reviewed · How we verify
NK-92 cells
At a glance
| Generic name | NK-92 cells |
|---|---|
| Sponsor | University Health Network, Toronto |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Constipation
- Abdominal pain
- Nausea
- Vomiting
- Infusion related reaction
- Hypoglycaemia
- Back pain
- Abdominal distension
- Diarrhoea
- Dyspepsia
- Asthenia
Key clinical trials
- PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC (PHASE2)
- Personalized NK Cell Therapy in CBT (PHASE2)
- Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (PHASE1)
- NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors (PHASE1)
- QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL (PHASE1, PHASE2)
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (PHASE1, PHASE2)
- QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy (PHASE1, PHASE2)
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NK-92 cells CI brief — competitive landscape report
- NK-92 cells updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI